Full text loading...
薬理と治療
Abstract
Background In recent years, a number of innovative drugs have emerged that show innovative evidence of effectiveness. Both of them meet the medical needs of the patients, but they often involve high drug priced and high volumes, especially in the short-term increase in drug costs immediately after launch, and the financial impact to budget in government. The Japanese market must be stable and attractive in order for Japan to continue to be the first in the world to provide innovative medicines with priority and continuity. Methods In order to specify and discuss the issues, a workshop entitled“Workshop on the Significance and Challenges of Pharmaceutical Innovation Evaluation”was held in August and December 2019. Furthermore, in order to visualize the current situation and identify budget impacts, we analyzed data with Japanese high priced and high-volume drugs. Results The issues were specified, and the evaluation of innovative drugs within the available financial resources and the introduction of a drug pricing system based on the evaluation were examined. We considered incentives to reflect the value of pharmaceuticals, setting special priority for innovative drugs, macroeconomic slides to secure resources for special priority, limiting drug costs, and adjusting allocation ratios. Conclusion We discussed the drug price system in different shades, such as the establishment of special priority subject to appropriate valuation and restrictions on the scale of drug costs. We hope that this issue and discussion will be discussed in more places, and in addition to how insurance benefits should be provided, based on the opinions of the public.
Data & Media loading...